1193-P: Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

EMPRISE studies the comparative effectiveness, safety and health care resource utilization of empagliflozin (EMPA) in Medicare and 2 U.S. commercial claims datasets (2014-2019). In this first analysis, we evaluated healthcare costs and medications burden associated with EMPA vs. dipeptidyl peptidase 4 inhibitors (DPP-4i) use in routine care patients with type 2 diabetes (T2D). We identified a 1:1 propensity-score-matched cohort of T2D patients...